B-Cell Malignancies

All categories, Deals and Financing, Technology Modalities

Nava Therapeutics Emerges With $89M for Precision RNA-LNP Delivery

Nava Therapeutics disclosed $89 million in financing to advance a precision lipid-nanoparticle platform designed to deliver RNA beyond the liver, including to immune cells and kidney tissue. The company is developing in vivo CAR-T…

admin
July 15, 2026

All categories, Technology Modalities

China BTK Challenger Enters Western Markets

InnoCare presented more than 40 orelabrutinib studies at EHA 2026, including the first treatment-naive CLL/SLL clinical data from US and European patients.

admin
June 15, 2026

All categories, Deals and Financing

Nurix + Roche; Global BTK Degrader Collaboration

Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.

admin
June 8, 2026

Nava Therapeutics Emerges With $89M for Precision RNA-LNP Delivery

China BTK Challenger Enters Western Markets

Nurix + Roche; Global BTK Degrader Collaboration

Weekly Market Insight